Evotec stock: Gates Foundation awards $2.9 million grant
Published on 11/16/2026 at 17:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGrant extends safety research
- Evotec is extending a Gates Foundation-backed project that uses human stem cell models to assess fetal development risks from drug candidates.
- The funding gives global health researchers continued access to Evotec's screening platform and supports earlier decisions in drug development.
Evotec announced on Monday, November 16, that the Gates Foundation awarded the company a new $2.9 million grant for a further three years of early drug safety research. The Financial Times company-announcement page carried the release from Evotec SE.
Human cell models support screening
The grant extends a project launched in 2023 that helps global health researchers identify potential risks to fetal development in novel drug candidates. Evotec's platform combines human induced pluripotent stem cell models with industrial-scale screening capabilities.
The approach is intended to provide human-relevant safety information earlier in drug discovery. That can help researchers decide which candidates should advance toward clinical testing and reduce the risk of costly changes later in development.
Platform remains collaboration asset
Evotec said the initial three-year collaboration screened more than 5,000 compounds across nine grantee programs. The company described the continued funding as support for its broader New Approach Methodologies portfolio, which includes human stem cell-derived models, organoid systems, AI-supported disease modeling and high-throughput screening.
Evotec stock traded at 2.96 euros on Lang & Schwarz at 17:14 CET on Monday, November 16, 2026.
Evotec company details
- Company: Evotec SE
- ISIN: DE0005664809
- Frankfurt ticker: EVT
- Price: 2.96 euros at Lang & Schwarz, 17:14 CET, November 16, 2026
Broader market conditions can be followed in Current market reports.
